Peter Marks joins former FDA colleague, Rachael Anatol at Eli Lilly, becoming the second agency worker the pharma has snapped ...

The growing strength of China’s drug pipelines has gone hand-in-hand with a steep uptick in big pharma licensing deals.

Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at ...

Oragenics has announced a strategic collaboration with Receptor.AI to expedite the development of a new pharmaceutical ...

To address this, many warehouse operations managers are turning to automation, including robotics, to reduce the strain on ...

Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m ...

The lifting of the FDA’s clinical hold on Neurizon’s drug will pave the way for its investigation in the HEALEY-ALS trial.

The completion of the Series A marks a fast-moving year for Trogenix, which only emerged from stealth in November 2024. The ...

Through the FDA's ANDA scheme, drug manufacturers who test and produce their generic medicines on US soil can now seek ...

Health Canada has approved Santhera Pharmaceuticals’ Agamree (vamorolone) drug for treating Duchenne muscular dystrophy (DMD) ...

This culminated in a $500m funding cut to mRNA vaccine research funding, impacting around 22 projects being run at the ...